Cantor Fitzgerald analyst Sarah James maintains Amedisys (NASDAQ:AMED) with a Neutral and raises the price target from $100 to $101.
Cantor Fitzgerald Maintains Neutral on Amedisys, Raises Price Target to $101
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.